Journal Mobile Options
Table of Contents
Vol. 39, No. 4, 2007
Issue release date: June 2007

Prognostic Significance of Pre- and Postoperative Serum Carcinoembryonic Antigen Levels in Patients with Colorectal Cancer

Wang J.Y. · Lu C.Y. · Chu K.S. · Ma C.J. · Wu D.C. · Tsai H.L. · Yu F.J. · Hsieh J.S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: To evaluate the prognostic significance of pre- and postoperative serum carcinoembryonic antigen(CEA) levels in colorectal cancer (CRC) patients. Methods: 425 CRC patients underwent curative resection at our institution. Their pre- and postoperative serum CEA level was classified into two groups according to concentration: normal CEA (<5.0 ng/ml) and abnormal CEA (≧5.0 ng/ml). Results: Of all patients, abnormal pre- and postoperative serum CEA levels were observed in 181 (42.6%) and 48 (11.3%) patients, respectively. Abnormal preoperative serum CEA level was significantly correlated with the tumor located in the colon, the depth of tumor invasion, the status of lymph node metastasis, UICC stage, and the presence of postoperative relapse (p < 0.05). Concurrently, an abnormal postoperative serum CEA level was also prominently related to the above corresponding parameters (p < 0.05), except for the tumor location. Patients with a failed conversion of abnormal preoperative value to normal postoperative concentration were found to have the worst overall survival rate. Abnormal pre- and postoperative serum CEA levels were single independent predictors for survival and postoperative relapse, respectively. Conclusions: The identification of abnormal pre- and postoperative serum CEA levels may be useful in the auxiliary cancer prognosis or postoperative surveillance of CRC patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Macdonald JS: Adjuvant therapy of colorectal cancer. CA Cancer J Clin 1999;49:202–219.
  2. International Union Against Cancer: TNM classification of malignant tumors, ed 6. New York, Wiley-Liss, 2002.
  3. Klee GG, Go VJW: Carcinoembryonic antigen and its role in clinical practice; in Ghosh BC, Ghosh L (eds): Tumor Markers and Tumor-Associated Antigens. New York, McGraw-Hill, 1990, pp 22–43.
  4. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467–481.
  5. Wanebo HJ, Rao B, Pinsky CM: The use of preoperative carcinoembryonic antigen level as a prognostic indicator to complement pathological staging. N Engl J Med 1978;299:448–451.
  6. Chu D, Erickson CA, Russell P, Thompson C, Lang NP, Broadwater RJ, Westbrook KC: Prognostic significance of carcinoembryonic antigen in colorectal cancer. Arch Surg 1991;125:314–316.
  7. Harrison LE, Guillem JG, Paty P, Cohen AM: Preoperative carcinoembryonic antigen predicts outcome in node negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997;1185:55–59.

    External Resources

  8. Watine J, Miedouge M, Friedberg B: Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis Colon Rectum 2001;44:1791–1799.
  9. Wiratkapun S, Kraemer M, Seow-Choen F, Ho YH, Eu KW: High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 2001;44:231–235.
  10. McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, Toouli J: The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994;37:875–881.
  11. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000;88:1739–1757.
  12. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979–994.
  13. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718–727.
  14. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, D’Alessandro R, Fracasso PL, Casale V, Vecchione A, Casciani CU, Greiner JW, Schlom J: Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int J Cancer 1997;72:949–954.
  15. Forslund A, Engarås B, Lönnroth C, Lundholm K: Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA50, CA242 and conventional blood tests in patients with colorectal carcinoma. Int J Oncol 2000;20:1013–1018.
  16. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C: Serum HCG-β, CA72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002;101:545–548.
  17. Slentz K, Senagore A, Hibbert J, Mazier WP, Talbott TM: Can preoperative and postoperative CEA predict survival after colon cancer resection? Am Surg 1994;60:528–531.
  18. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC: Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 2005;124:169–174.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50